The selective estrogen receptor modulator raloxifene inhibits cardiac delayed rectifier potassium currents and voltage-gated sodium current without QTc interval prolongation

Pharmacological Research

Volumn 62, Issue 5, 2010, Pages 384-390

  Liu, Hui ^a   Yang, Lei ^a   Jin, Man Wen ^a   Sun, Hai Ying ^c   Huang, Yu ^b   Li, Gui Rong ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Delayed rectifier potassium currents; QTc interval; Raloxifene; Voltage gated sodium current

Indexed keywords

POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNQ1; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GUINEA PIG; HEART MUSCLE CELL; HEART VENTRICLE; HUMAN; HUMAN CELL; IC 50; ISOLATED HEART; MALE; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; SODIUM CURRENT;

EID: 77956941034     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.07.008     Document Type: Article

References (52)

1. De Bruin M.L., Pettersson M., Meyboom R.H., Hoes A.W., Leufkens H.G. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 2005, 26:590-597.
2. De Ponti F., Poluzzi E., Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 2000, 56:1-18.
3. Haverkamp W., Breithardt G., Camm A.J., Janse M.J., Rosen M.R., Antzelevitch C., et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Cardiovasc Res 2000, 47:219-233.
4. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 2004, 350:1013-1022.
5. Sanguinetti M.C., Mitcheson J.S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 2005, 26:119-124.
6. Wible B.A., Hawryluk P., Ficker E., Kuryshev Y.A., Kirsch G., Brown A.M. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 2005, 52:136-145.
7. Riggs B.L., Hartmann L.C. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003, 348:618-629.
8. Rey J.R., Cervino E.V., Rentero M.L., Crespo E.C., Alvaro A.O., Casillas M. Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. Open Orthop J 2009, 3:14-21.
9. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
10. Mitchner N.A., Harris S.T. Current and emerging therapies for osteoporosis. J Fam Pract 2009, 58:S45-S49.
11. Lewis J.S., Jordan V.C. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005, 591:247-263.
12. Pearman L., Kagan R., Arsenault J., Muram D. The effects of raloxifene on mammographic breast density: a review of clinical trials. Menopause 2010, 17:654-659.
13. Ogita H., Node K., Asanuma H., Sanada S., Takashima S., Asakura M., et al. Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J Cardiol 2002, 39:55-56.
14. Ogita H., Node K., Asanuma H., Sanada S., Kim J., Takashima S., et al. Raloxifene improves coronary perfusion, cardiac contractility, and myocardial metabolism in the ischemic heart: role of phosphatidylinositol 3-kinase/Akt pathway. J Cardiovasc Pharmacol 2004, 43:821-829.
15. Liew R., Stagg M.A., MacLeod K.T., Collins P. Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current. Br J Pharmacol 2004, 142:89-96.
16. Liu H., Jin M.W., Xiang J.Z., Huang Y., Sun H.Y., Chiu S.W., et al. Raloxifene inhibits transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes. Eur J Pharmacol 2007, 563:61-68.
17. Kr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 1998, 287:877-883.
18. Song J., Standley P.R., Zhang F., Joshi D., Gappy S., Sowers J.R., et al. Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J Pharmacol Exp Ther 1996, 277:1444-1453.
19. Pollack I.F., DaRosso R.C., Robertson P.L., Jakacki R.L., Mirro J.R., Blatt J., et al. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 1997, 3:1109-1115.
20. Trump D.L., Smith D.C., Ellis P.G., Rogers M.P., Schold S.C., Winer E.P., et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992, 84:1811-1816.
21. Thomas D., Gut B., Karsai S., Wimmer A.B., Wu K., Wendt-Nordahl G., et al. Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. Naunyn Schmiedebergs Arch Pharmacol 2003, 368:41-48.
22. Dong M.Q., Lau C.P., Gao Z., Tseng G.N., Li G.R. Characterization of recombinant human cardiac KCNQ1/KCNE1 channels (I (Ks)) stably expressed in HEK 293 cells. J Membr Biol 2006, 210:183-192.
23. Dong M.Q., Sun H.Y., Tang Q., Tse H.F., Lau C.P., Li G.R. Regulation of human cardiac KCNQ1/KCNE1 channel by epidermal growth factor receptor kinase. Biochim Biophys Acta 2010, 1798:995-1001.
24. Tang Q., Li Z.Q., Li W., Guo J., Sun H.Y., Zhang X.H., et al. The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-a-go-go-related gene (hERG) potassium channels. Br J Pharmacol 2008, 155:365-373.
25. Zhang D.Y., Wang Y., Lau C.P., Tse H.F., Li G.R. Both EGFR kinase and Src-related tyrosine kinases regulate human ether-a-go-go-related gene potassium channels. Cell Signal 2008, 20:1815-1821.
26. Trudeau M.C., Warmke J.W., Ganetzky B., Robertson G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995, 269:92-95.
27. Van de W.A., Verheyen J., Xhonneux R., Reneman R.S. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 1989, 22:207-217.
28. Takahara A., Sugiyama A., Hashimoto K. Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation. Br J Pharmacol 2005, 146:561-567.
29. Liu H., Sun H.Y., Lau C.P., Li G.R. Regulation of voltage-gated cardiac sodium current by epidermal growth factor receptor kinase in guinea pig ventricular myocytes. J Mol Cell Cardiol 2007, 42:760-768.
30. Li G.R., Lau C.P., Shrier A. Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts. J Mol Cell Cardiol 2002, 34:1185-1194.
31. Tian M., Dong M.Q., Chiu S.W., Lau C.P., Li G.R. Effects of the antifungal antibiotic clotrimazole on human cardiac repolarization potassium currents. Br J Pharmacol 2006, 147:289-297.
32. Tang Q., Jin M.W., Xiang J.Z., Dong M.Q., Sun H.Y., Lau C.P., et al. The membrane permeable calcium chelator BAPTA-AM directly blocks human ether-a-go-go-related gene potassium channels stably expressed in HEK 293 cells. Biochem Pharmacol 2007, 74:1596-1607.
33. Kamiya K., Mitcheson J.S., Yasui K., Kodama I., Sanguinetti M.C. Open channel block of HERG K(+) channels by vesnarinone. Mol Pharmacol 2001, 60:244-253.
34. + currents in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2003, 285:H661-H668.
35. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990, 96:195-215.
36. + channel blocker-induced QT-interval prolongation. Biol Pharm Bull 2006, 29:827-829.
37. Yang Z., Shi G., Li C., Wang H., Liu K., Liu Y. Electrophysiologic effects of nicorandil on the guinea pig long QT1 syndrome model. J Cardiovasc Electrophysiol 2004, 15:815-820.
38. 2+ channels. Stroke 2004, 35:1709-1714.
39. Wenger N.K. Cardiovascular effects of raloxifene: the potential for cardiovascular protection in women. Diabetes Obes Metab 2002, 4:166-176.
40. Cano A., Hermenegildo C., Oviedo P., Tarin J.J. Selective estrogen receptor modulators and risk for coronary heart disease. Climacteric 2007, 10:97-111.
41. Shimizu W., Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000, 35:778-786.
42. Zhang S., Zhou Z., Gong Q., Makielski J.C., January C.T. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 1999, 84:989-998.
43. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003, 58:32-45.
44. Li G.R., Ferrier G.R. Verapamil prevents slowing of transmural conduction and suppresses arrhythmias in an isolated guinea pig ventricular model of ischemia and reperfusion. Circ Res 1992, 70:651-659.
45. Aiba T., Shimizu W., Inagaki M., Noda T., Miyoshi S., Ding W.G., et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 2005, 45:300-307.
46. Yuill K.H., Borg J.J., Ridley J.M., Milnes J.T., Witchel H.J., Paul A.A., et al. Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphene-without QT interval prolongation. Biochem Biophys Res Commun 2004, 318:556-561.
47. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989, 321:406-412.
48. Moller C., Netzer R. Effects of estradiol on cardiac ion channel currents. Eur J Pharmacol 2006, 532:44-49.
49. Li G.R., Feng J., Yue L., Carrier M. Transmural heterogeneity of action potentials and Ito1 in myocytes isolated from the human right ventricle. Am J Physiol Heart Circ Physiol 1998, 275:H369-H377.
50. Li G.R., Lau C.P., Leung T.K., Nattel S. Ionic current abnormalities associated with prolonged action potentials in cardiomyocytes from diseased human right ventricles. Heart Rhythm 2004, 1:460-468.
51. Heringa M. Review on raloxifene: profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther 2003, 41:331-345.
52. Traina T.A., Poggesi I., Robson M., Asnis A., Duncan B.A., Heerdt A., et al. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat 2008, 111:377-388.